Improving outcomes for cancer patients by targeting the epigenome

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1196749

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The most commonly mutated proteins in cancer involve so called epigenetic regulators, a class of proteins that regulate access to our DNA to control gene expression, DNA repair and replication. We and others have recently developed a variety of drugs to help inhibit the aberrant activity of these epigenetic proteins. My research will focus on ways to improve the efficacy of these existing drugs and find new epigenetic therapies to improve the survival of patients with a broad range of cancers.

Funded Activity Details

Start Date: 01-01-2020

End Date: 01-01-2020

Funding Scheme: Investigator Grants

Funding Amount: $2,258,892.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

epigenetics | leukaemia | transcriptional regulation | translational research

Related Links